BIOA (Bioage Labs) Price-to-Operating-Cash-Flow : (As of May. 30, 2025)

View and export this data going back to 2024. Start your Free Trial

What is Bioage Labs Price-to-Operating-Cash-Flow?

As of today (2025-05-30), Bioage Labs's share price is $3.97. Bioage Labs's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was $-5.36. Hence, Bioage Labs's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Bioage Labs's Price-to-Operating-Cash-Flow or its related term are showing as below:

BIOA's Price-to-Operating-Cash-Flow is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 17.14
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Bioage Labs's Cash Flow from Operations per share for the three months ended in Mar. 2025 was $-0.48. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was $-5.36.

Bioage Labs Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Bioage Labs's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioage Labs Price-to-Operating-Cash-Flow Chart

Bioage Labs Annual Data

Trend

Dec22

Dec23

Dec24

Price-to-Operating-Cash-Flow

Bioage Labs Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial					-	-	-	-	-

Competitive Comparison of Bioage Labs's Price-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Bioage Labs's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioage Labs's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bioage Labs's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Bioage Labs's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

Bioage Labs Price-to-Operating-Cash-Flow Calculation

Bioage Labs's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	3.97	/	-5.361
	=

Bioage Labs's Share Price of today is $3.97.
Bioage Labs's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.36.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Bioage Labs Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Bioage Labs's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioage Labs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bioage Labs Inc (NAS:BIOA) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

Y7G:Germany

Address

1445A South 50th Street, Richmond, CA, USA, 94804

Website

https://www.bioagelabs.com

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.